From regulatory shifts to smarter trial execution, this edition brings practical insights for sponsors navigating early-phase studies across Latin America and Australia. Whether you're streamlining startup processes or refining trial design, you’ll find strategic updates to move you
regulatory · FDA · AI · decentralized · RWD
From regulatory shifts to smarter trial execution, this edition brings practical insights for sponsors navigating early-phase studies across U.S. regulatory anchoring plus U.S. and Latin America execution. Whether youre streamlining startup processes or refining trial design, youll find strategic updates to move your programs forward.
Let’s dive into whats shaping the future of clinical trials. 👇
The FDA has announced expanded regulatory flexibility for cell and gene therapies, offering science-based, risk-adjusted expectations around chemistry, manufacturing, and control (CMC) requirements.
This shift is designed to support faster development of small-batch, individualized therapies—without compromising safety, purity, or potency. Key Points:
Why It Matters: This is a significant step forward for Biopharma innovators working in complex therapeutic areas.
By reducing CMC-related friction, sponsors can move more confidently through early-phase development and global trial startup—especially in emerging regions like Latin America, the Balkans, and Australia.
Source: https://www.fda.gov
As global interest in synthetic control arms and real-world data grows, Latin America presents both promise and complexity.
While the regions RWD infrastructure is still evolving, sponsors who take a thoughtful, site-specific approach can unlock valuable insights without overreaching.
Its not about avoiding innovation—its about aligning strategy with reality.
By focusing on hybrid models, investing in data quality, and partnering with experienced sites, Medtech teams can build strong foundations for future-ready clinical evidence.
The path is there—it just requires the right map.
Source: https://www.meddeviceonline.com
As decentralized and hybrid models become more common in clinical research, the FDA is reinforcing the need for strong sponsor oversight.
Digital tools like wearables, apps, and eConsent platforms must be managed with clear documentation, defined roles, and secure data practices—all while maintaining full compliance with Good Clinical Practice (GCP) standards.
This added clarity helps trial teams adopt decentralized strategies with more confidence.
When oversight structures are sound, hybrid trials can improve access, streamline operations, and support scalability across diverse clinical environments.
Source: https://www.clinicalleader.com
Does Your Company Need Accelerated First-in-Human Clinical Trial Results?
Overcome the complex landscape of first-in-human clinical trials with confidence.
Whether youre advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Schedule Your First-in-Human Trial Consult
Regulatory speed can make or break a study launch—and Mexico offers real advantages if you know how to navigate the system.
From ethics approvals to Cofepris timelines, understanding the sequencing and documentation requirements can unlock faster startup and smoother execution.
A quick self-check can reveal whether your team is truly prepared or just guessing.
Bottom Line:
Sponsors who master Mexicos regulatory roadmap position themselves for faster site activation, fewer delays, and stronger execution in one of Latin Americas most trial-friendly environments.
Source: https://www.bioaccessla.com
Gordian Bio has partnered with Pfizer to explore novel obesity treatments using a high-throughput in vivo screening platform that tests thousands of gene targets directly in visceral fat tissue.
This approach allows researchers to uncover new biological pathways related to inflammation, metabolism, and insulin resistance—providing a more accurate, scalable way to identify therapeutic candidates beyond todays standard GLP-1 strategies.
The collaboration highlights a growing industry shift toward early-stage platforms that improve the efficiency and precision of drug discovery.
As pharma companies invest in tools that reduce translational risk, partnerships like this signal a new phase in how complex metabolic diseases are tackled from the ground up.
Source: https://longevity.technology
AI is gaining real traction in early-phase drug development, with the potential to accelerate timelines, reduce costs, and bring more targeted therapies to patients.
Matteo Talotta, Director of Clinical Solutions at Biorce, highlights how AI is being used to rapidly analyze trial data, predict outcomes, and drive precision medicine by processing complex genomic and patient-level information.
As the technology evolves, combining AI with clinical expertise is becoming a strategic advantage for sponsors aiming to streamline development and improve success rates.
The future of clinical research may not be AI-driven alone—but it will certainly be AI-enabled.
Source: https://www.linkedin.com
← All Global Trial Accelerators editions · Contact bioaccess®